Trial Profile
A Phase 2b study of OPK88004 evaluating optimal dosing for type 2 diabetes and obesity
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2017
Price :
$35
*
At a glance
- Drugs Oxyntomodulin (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors OPKO Health
- 05 Jul 2017 New trial record
- 09 May 2017 According to an OPKO Health media release, the company plans to initiate this trial in early 2018.